Aktienanalyse zu InflaRx NV (IFRX)IFRXInflaRx NV

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development. It operates in the Financials sector.

InflaRx NV (IFRX) is a good buy right now due to its current price of $1.765, which is significantly below the analyst price target of $8 from Needham and $9 from Raymond James. The stock has shown a strong year-to-date change of +61.93% and a recent 5-day change of +12.06%, indicating positive momentum. However, the main risk is the company's negative earnings per share (EPS) estimate of -0.07 for the upcoming earnings report on November 9, which could impact investor sentiment.

3 analysts cover IFRX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.67.